GO:0008269 JAK pathway signal transduction adaptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008269 (JAK pathway signal transduction adaptor activity) is a molecular function defined as the binding activity of a molecule that brings together two molecules of the JAK signal transduction pathway, permitting them to function in a coordinated way.
• Adaptor proteins with this activity nucleate and stabilize signaling complexes that link cytokine and interferon receptors to JAK-STAT activation.
• Key adaptors and regulators include JAKs, STATs, SOCS proteins, LNK/SH2B3, and MYD88, which together tune the amplitude and duration of JAK pathway output.
• Dysregulated JAK pathway adaptor function is implicated in hematological malignancies, lymphoma, and solid tumors, and can drive resistance to tyrosine kinase inhibitors.
• Loss or restriction of negative adaptors such as SOCS1 can amplify interferon-gamma responses, linking adaptor activity to immune regulation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test whether candidate adaptors are causally required for JAK-STAT signaling.
Description
GO:0008269, JAK pathway signal transduction adaptor activity, is a molecular function that describes the binding activity of a molecule that brings together two molecules of the JAK signal transduction pathway, permitting them to function in a coordinated way. In practice, this activity is performed by adaptor and scaffold proteins that assemble receptor-proximal signaling complexes, allowing Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins to communicate efficiently after cytokine or interferon stimulation. Because JAK-STAT signaling is a central route by which extracellular cues are converted into transcriptional programs, the adaptors that organize this pathway are critical nodes for both normal physiology and disease. The JAK-STAT cascade is activated by type I and type II interferons and by numerous cytokines, and its output depends on the coordinated assembly of receptor, kinase, and adaptor components. Adaptor activity in this pathway is not merely passive: adaptors determine which JAKs and STATs are recruited, how long the signal persists, and whether negative regulators such as SOCS proteins are engaged. Consequently, mutations or expression changes in JAK pathway adaptors can rewire signaling in hematological malignancies and solid tumors. For researchers, GO:0008269 provides a precise functional annotation to interpret gene lists, CRISPR screens, and interactome data. Understanding which proteins carry JAK pathway signal transduction adaptor activity, and how they are regulated, is essential for dissecting cytokine signaling, immune evasion, and resistance to targeted therapies. This article summarizes the definition, mechanism, key genes, disease links, and experimental models relevant to GO:0008269.
JAK pathway signal transduction adaptor activity At A Glance
| GO ID | GO:0008269 |
|---|---|
| GO term | JAK pathway signal transduction adaptor activity |
| Ontology | molecular_function |
| Synonym | None listed in QuickGO |
| Major function | Binding activity that brings together two molecules of the JAK signal transduction pathway for coordinated function |
| Pathway context | JAK-STAT cytokine and interferon signaling |
| Representative proteins | JAKs, STATs, SOCS proteins, LNK/SH2B3, MYD88 |
| Disease relevance | Hematological malignancies, lymphoma, solid tumors, therapy resistance |
What Is GO:0008269?
GO:0008269 is defined by QuickGO as the binding activity of a molecule that brings together two molecules of the JAK signal transduction pathway, permitting them to function in a coordinated way. In other words, it is an adaptor or scaffold function: the annotated protein does not necessarily catalyze a reaction, but it physically bridges two pathway components so that they can act together. This activity is distinct from kinase activity or transcription factor activity, although it is required for efficient JAK-STAT signal transduction.
Why Is JAK pathway signal transduction adaptor activity Important in Cell Biology?
JAK pathway signal transduction adaptor activity is important because it determines how effectively cytokine and interferon signals are converted into STAT-mediated transcription. Adaptors that carry this activity organize receptor-proximal complexes, influence signal strength and duration, and connect JAK-STAT signaling to negative feedback regulators such as SOCS proteins. Because these processes control immune responses, hematopoiesis, and cell growth, their dysregulation contributes to cancers and inflammatory disease, and they are actively pursued as therapeutic targets.
• Defines a specific molecular function that links cytokine receptors to JAK-STAT activation.
• Enables coordinated assembly of JAKs, STATs, and receptor subunits at the membrane.
• Controls the amplitude and duration of interferon and cytokine signaling.
• Provides a mechanistic explanation for how adaptor mutations can drive hematological malignancies.
• Connects oncogenic signaling such as MYD88 activation to JAK pathway output in lymphoma.
• Links glycosylation and secretion of cytokines to downstream JAK pathway activity in lung cancer.
• Influences resistance to tyrosine kinase inhibitors and other targeted therapies.
• Offers candidate biomarkers and therapeutic nodes for immune and cancer research.
• Supports functional genomics studies using CRISPR screens and interactome mapping.
• Helps interpret GO enrichment in transcriptomic and proteomic datasets focused on cytokine signaling.
What Happens During JAK pathway signal transduction adaptor activity?
Receptor engagement and adaptor recruitment
In simple terms: When a cytokine or interferon binds its receptor, adaptor proteins help bring the right signaling molecules together.
Type I and type II interferons and many cytokines activate the JAK-STAT pathway by inducing receptor dimerization or conformational changes that recruit JAK kinases and adaptor proteins. Adaptors with GO:0008269 activity bind receptor-proximal components and stabilize the signaling complex, ensuring that JAKs and STATs are positioned for coordinated activation.
JAK activation and STAT phosphorylation
In simple terms: Once assembled, JAK kinases turn on and tag STAT proteins so they can move to the nucleus.
After adaptor-mediated assembly, JAK kinases phosphorylate each other and the receptor cytoplasmic tails, creating docking sites for STAT proteins. STATs are then phosphorylated by JAKs, dimerize, and translocate to the nucleus to regulate transcription. Adaptor activity in this step ensures that the kinase and substrate are brought into proximity, which is the essence of GO:0008269.
Negative feedback by SOCS proteins
In simple terms: The pathway has brakes, and adaptor-like proteins such as SOCS help shut the signal off.
SOCS proteins are induced by JAK-STAT signaling and act as negative regulators by binding JAKs or receptors and limiting further activation. Recent work shows that ARAP2 restricts SOCS1 to regulate interferon-gamma responses, illustrating how adaptor and trafficking proteins shape the duration of JAK pathway output. This feedback is essential to prevent excessive cytokine signaling.
Crosstalk with oncogenic and metabolic pathways
In simple terms: JAK pathway adaptors do not work alone; they connect to cancer and metabolism signals.
Adaptor activity in the JAK pathway intersects with oncogenic drivers such as MYD88 mutations in lymphoma, which sustain survival signaling. In lung cancer, defective N-glycosylation of IL6 alters cytokine signaling and contributes to tyrosine kinase inhibitor resistance, highlighting how upstream changes feed into JAK pathway adaptor function. LNK/SH2B3 acts as a negative adaptor whose dysfunction is linked to juvenile myelomonocytic leukemia.
Key Genes Involved in GO:0008269 JAK pathway signal transduction adaptor activity
The following genes and proteins are representative components, adaptors, or regulators associated with JAK pathway signal transduction adaptor activity (GO:0008269).
| Gene | Major Role | Research Relevance |
|---|---|---|
| JAK1 | Janus kinase that phosphorylates STATs after cytokine receptor engagement | Core kinase in type I and type II interferon signaling |
| JAK2 | Janus kinase mediating cytokine and interferon signal transduction | Frequently studied in hematological malignancies |
| TYK2 | Janus kinase involved in type I interferon and cytokine signaling | Component of JAK-STAT adaptor complexes |
| STAT1 | Transcription factor activated downstream of JAKs | Central mediator of interferon responses |
| STAT3 | Transcription factor regulating proliferation and survival | Oncogenic node in many cancers |
| SOCS1 | Negative regulator of JAK-STAT signaling | Restricted by ARAP2 to control interferon-gamma responses |
| SOCS3 | Negative feedback regulator of cytokine signaling | Modulates JAK pathway duration |
| LNK/SH2B3 | Adaptor protein that negatively regulates cytokine signaling | Driver in juvenile myelomonocytic leukemia |
| MYD88 | Adaptor protein in innate immune signaling | Oncogenically active mutations in human lymphoma |
| ARAP2 | Regulator of SOCS1 trafficking and interferon-gamma responses | Controls JAK pathway output |
| IL6 | Cytokine upstream of JAK-STAT activation | N-glycosylation defects linked to metastasis and TKI resistance |
| IFNAR1 | Type I interferon receptor subunit | Initiates JAK pathway assembly |
| IFNAR2 | Type I interferon receptor subunit | Recruits JAKs and adaptors |
| IFNGR1 | Type II interferon receptor subunit | Mediates interferon-gamma signaling |
| IFNGR2 | Type II interferon receptor subunit | Part of the interferon-gamma receptor complex |
| PTPN11 | Protein tyrosine phosphatase SHP2 | Modulates JAK-STAT signaling |
| CBL | E3 ubiquitin ligase and adaptor | Regulates receptor turnover in JAK pathway |
| GRB2 | Adaptor protein linking receptors to downstream pathways | General adaptor relevant to JAK pathway crosstalk |
How Is JAK pathway signal transduction adaptor activity Regulated?
JAK pathway signal transduction adaptor activity is regulated at multiple levels. SOCS proteins provide negative feedback by binding JAKs or receptor subunits and limiting signal duration. ARAP2 restricts SOCS1 availability, thereby tuning interferon-gamma responses. LNK/SH2B3 acts as a negative adaptor whose loss enhances cytokine signaling and contributes to juvenile myelomonocytic leukemia. Oncogenic mutations such as MYD88 L265P can sustain JAK pathway output in lymphoma. In addition, post-translational modifications and glycosylation of upstream cytokines such as IL6 can alter JAK-STAT activation and therapy response.
JAK pathway signal transduction adaptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LNK/SH2B3 | Juvenile myelomonocytic leukemia | Knockout and point-mutation models in hematopoietic cells |
| MYD88 | Human lymphoma | Knock-in of L265P mutation in B-cell lines |
| IL6 | Lung cancer metastasis and TKI resistance | Overexpression and glycosylation-site mutants |
| SOCS1 | Interferon-gamma immune regulation | Knockout and tagged knock-in for trafficking studies |
| JAK2 | Myeloproliferative neoplasms | Point-mutation knock-in models |
Hematological malignancies
Dysregulated JAK-STAT signaling is a hallmark of several hematological malignancies, and adaptor proteins that organize this pathway are recurrently involved. LNK/SH2B3 dysfunction has been identified as a novel driver in juvenile myelomonocytic leukemia, linking negative adaptor function to myeloid disease. These findings support the view that GO:0008269 activity is a key determinant of malignant transformation in blood cells.
Lymphoma and oncogenic adaptors
Oncogenically active MYD88 mutations in human lymphoma activate survival signaling that intersects with JAK pathway components. Because MYD88 is an adaptor protein, this illustrates how adaptor activity outside the canonical JAK-STAT module can feed into and sustain JAK pathway output, making it a therapeutic target in B-cell malignancies.
Solid tumors and therapy resistance
In lung cancer, defective N-glycosylation of IL6 promotes metastasis and tyrosine kinase inhibitor resistance, a process that involves altered cytokine signaling upstream of JAK-STAT. Resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription also highlight the complexity of signaling networks that intersect with JAK pathway adaptors. Together, these studies show that adaptor activity in the JAK pathway can influence drug response in solid tumors.
Immune regulation and interferonopathies
ARAP2 regulates responses to interferon-gamma by restricting SOCS1, demonstrating that adaptor and trafficking proteins control the intensity of JAK-STAT signaling. Imbalances in this regulation can lead to excessive or insufficient immune responses, underscoring the importance of GO:0008269 in immune homeostasis.
From JAK pathway signal transduction adaptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is the candidate adaptor required for JAK-STAT activation? | CRISPR knockout cell line |
| Does a specific point mutation alter adaptor binding? | Point-mutation knock-in |
| Where does the adaptor localize in the signaling complex? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression amplify cytokine signaling? | Overexpression cell model |
| Which genes modify JAK pathway output genome-wide? | CRISPR library screening |
| How does adaptor loss affect transcription? | RNA-seq after knockout |
How to Study the JAK pathway signal transduction adaptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function phenotype | Testing requirement for JAK-STAT signaling |
| Point-mutation knock-in | Effect of specific variants | Modeling oncogenic adaptor mutations |
| RNA-seq | Transcriptional changes | Pathway profiling after adaptor perturbation |
| Proteomics / AP-MS | Protein interactions | Identifying adaptor complexes |
| Phospho-STAT immunoblot | JAK-STAT activation | Functional readout of adaptor activity |
| Proximity ligation assay | In situ protein proximity | Visualizing adaptor recruitment |
| CRISPR library screening | Genome-wide modifiers | Discovering regulators of JAK pathway output |
| Flow cytometry | Cell surface and intracellular markers | Immune cell phenotyping after perturbation |
CRISPR knockout and functional validation
CRISPR knockout is widely used to test whether a candidate adaptor is required for JAK-STAT signaling. Loss-of-function models for LNK/SH2B3 and other adaptors have clarified their roles in cytokine signaling and leukemia. Knockout followed by cytokine stimulation and STAT phosphorylation assays provides direct functional evidence for GO:0008269 activity.
Transcriptomics and pathway profiling
RNA-seq and pathway enrichment after perturbation can reveal how adaptor loss or mutation reshapes JAK-STAT target gene expression. Such datasets are often analyzed for GO terms including GO:0008269 to interpret signaling changes in cancer and immune cells.
Proteomics and interactome mapping
Affinity purification and mass spectrometry can identify proteins that physically bridge JAK pathway components, directly supporting adaptor activity annotations. These approaches help define which complexes carry GO:0008269 and how they change upon stimulation.
Imaging and spatial assays
Fluorescence microscopy and proximity ligation assays can visualize adaptor recruitment to receptors and co-localization with JAKs or STATs. Such methods complement biochemical assays by showing where adaptor activity occurs in cells.
How CRISPR Can Be Used to Study GO:0008269 JAK pathway signal transduction adaptor activity
Knockout
CRISPR knockout of candidate adaptors such as LNK/SH2B3 or SOCS1 allows researchers to test whether the protein is required for normal JAK-STAT signaling. Knockout cells can be stimulated with cytokines or interferons and assayed for STAT phosphorylation and target gene expression.
Point Mutation
Point-mutation knock-in is used to model disease-associated variants, such as oncogenic MYD88 mutations in lymphoma or JAK2 mutations in myeloproliferative neoplasms. These models help distinguish gain-of-function from loss-of-function effects on JAK pathway adaptor activity.
Knock-in
Tagged knock-in of adaptor genes enables localization and interaction studies without overexpression artifacts. Fluorescent or epitope tags can be introduced at endogenous loci to track adaptor recruitment to receptor complexes.
Overexpression
Overexpression models are useful for testing whether increased adaptor levels amplify JAK-STAT signaling, as seen with cytokine-driven pathways in cancer. They can also reveal dominant-negative or gain-of-function properties of mutant adaptors.
How EDITGENE Supports JAK pathway signal transduction adaptor activity Research
Researchers studying JAK pathway signal transduction adaptor activity-related genes often need to determine whether a candidate gene is causally involved in cytokine signaling, immune regulation, or cancer. EDITGENE provides publication-ready CRISPR cell models and screening services to test these hypotheses with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for JAK pathway signal transduction adaptor activity research.
Frequently Asked Questions About JAK pathway signal transduction adaptor activity
What is GO:0008269 JAK pathway signal transduction adaptor activity?
GO:0008269 is a molecular function defined as the binding activity of a molecule that brings together two molecules of the JAK signal transduction pathway, permitting them to function in a coordinated way.
What genes are involved in JAK pathway signal transduction adaptor activity?
Key genes include JAK1, JAK2, TYK2, STAT1, STAT3, SOCS1, SOCS3, LNK/SH2B3, MYD88, and ARAP2, among others.
Why is JAK pathway adaptor activity important in cancer?
Dysregulated adaptor function can sustain oncogenic signaling, as seen with MYD88 mutations in lymphoma and LNK/SH2B3 in juvenile myelomonocytic leukemia.
How do SOCS proteins regulate JAK pathway adaptor activity?
SOCS proteins act as negative feedback regulators that bind JAKs or receptors and limit signal duration. ARAP2 restricts SOCS1 to control interferon-gamma responses.
What experimental models are used to study GO:0008269?
CRISPR knockout, point-mutation knock-in, tagged knock-in, overexpression, and CRISPR library screening are commonly used to study JAK pathway adaptors.
Is JAK pathway signal transduction adaptor activity involved in interferon signaling?
Yes, type I and type II interferons activate JAK-STAT signaling, and adaptor proteins help assemble the receptor-proximal complexes required for this response.
What diseases are linked to JAK pathway adaptor dysfunction?
Hematological malignancies, lymphoma, lung cancer metastasis, and therapy resistance have been linked to altered JAK pathway adaptor function.
How can CRISPR screens identify JAK pathway adaptors?
Genome-wide CRISPR screens can reveal genes whose loss or gain alters JAK-STAT output, helping to identify novel adaptors and regulators.
What is the difference between JAK pathway adaptor activity and kinase activity?
Adaptor activity is a binding function that brings two pathway molecules together, whereas kinase activity catalyzes phosphorylation; both are needed for efficient JAK-STAT signaling.
How does IL6 glycosylation affect JAK pathway signaling?
Defective N-glycosylation of IL6 can alter cytokine signaling and contribute to metastasis and tyrosine kinase inhibitor resistance in lung cancer.
Conclusion
GO:0008269, JAK pathway signal transduction adaptor activity, captures a fundamental molecular function that organizes cytokine and interferon signaling. Adaptors carrying this activity ensure that JAKs, STATs, and receptors act in a coordinated manner, and their dysregulation is linked to hematological malignancies, lymphoma, and solid tumor therapy resistance. Understanding these proteins requires functional models that can test causality, such as CRISPR knockout, point-mutation knock-in, and overexpression systems. As research continues to map the adaptor networks that shape JAK-STAT output, GO:0008269 provides a useful annotation for interpreting genomic and proteomic data. Combining CRISPR models with transcriptomics, proteomics, and imaging will clarify how adaptor activity can be targeted in immune and cancer therapy.
References
- 1. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling.. Nat Rev Immunol 5(5):375-86 PMID: 15864272
- 2. Ngo VN et al.. 2011. Oncogenically active MYD88 mutations in human lymphoma.. Nature 470(7332):115-9 PMID: 21179087
- 3. Hung CH et al.. 2024. Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer.. Nat Commun 15(1):7885 PMID: 39251588
- 4. Wintering A et al.. 2024. LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia.. Haematologica 109(8):2533-2541 PMID: 38152053
- 5. Kulkarni A et al.. 2024. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.. EMBO Rep 25(9):3944-3969 PMID: 39103676
- 6. Keating N et al.. 2025. ARAP2 regulates responses to interferon-gamma by restricting SOCS1.. Cell Rep 44(12):116667 PMID: 41401070
- 7. Valentino L et al.. 2006. JAK/STAT signal transduction: regulators and implication in hematological malignancies.. Biochem Pharmacol 71(6):713-21 PMID: 16426581
- 8. Platanias LC et al.. 1999. Signaling pathways activated by interferons.. Exp Hematol 27(11):1583-92 PMID: 10560905
